pp-118 Solution for infusion

Indication: Cutaneous T-cell lymphomas (CTCL), including Sézary syndrome and mycosis fungoides, particularly in relapsed/refractory patients expressing KIR3DL2 Clinical stage: Phase 2 completed Modality: Biologic (humanized IgG1 monoclonal antibody) Mechanism / Target: Targets KIR3DL2, an inhibitory receptor selectively expressed on malignant T cells in CTCL; induces tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC) Route / form: Intravenous infusion Differentiation: First-in-class targeting of KIR3DL2, enabling biomarker-driven patient selection; demonstrates selective depletion of malignant T cells while sparing normal T-cell populations; favorable tolerability profile compared with conventional systemic therapies; positioned as a targeted therapy for advanced CTCL with high unmet need